Moderna Files Q1 2025 10-Q
Ticker: MRNA · Form: 10-Q · Filed: May 1, 2025 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
Moderna's Q1 2025 10-Q is in. Check financials.
AI Summary
Moderna, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations for the first quarter of 2025. Key financial data and operational updates are presented for investors and stakeholders.
Why It Matters
This filing provides investors with the latest financial and operational details for Moderna, Inc., crucial for understanding the company's performance in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, Moderna faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Moderna, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report
- 20250501 (date) — Filing date
- 325 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
The filing date (As Of Date) is 20250501.
What is Moderna, Inc.'s primary business classification?
Moderna, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the company's fiscal year end?
The fiscal year end for Moderna, Inc. is December 31.
What is the SEC file number for Moderna, Inc.?
The SEC File Number is 001-38753.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Moderna, Inc. (MRNA).